Payment overview · 2025
General Payments
$424.25
21 reported records · 9 companies
Healthcare provider profile · identity verified
Michael Odell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GREENEVILLE, TN · NPI 1477593143
Verified facts
What the public records show
CMS Open Payments records show Michael Odell, M.D. received $424.25 in general payments during 2025 across 21 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synjardy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $100.12 | 23.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.78 | 19.5% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $62.43 | 14.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.83 | 13.6% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.45 | 10.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.31 | 7.1% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.35 | 3.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.98 | 3.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.00 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $424.25 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $100.12 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $62.43 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.83 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.83 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.51 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.51 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $46.45 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.27 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 234 | 49 |
| Alprazolam | Alprazolam | 229 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 219 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 55 |
| Omeprazole | Omeprazole | 200 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 199 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 135 | 37 |
| Lisinopril | Lisinopril | 133 | 39 |
| Furosemide | Furosemide | 132 | 42 |
| Potassium Chloride | Potassium Chloride | 116 | 35 |
| Trazodone Hcl | Trazodone Hcl | 108 | 20 |
| Tramadol Hcl | Tramadol Hcl | 99 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 24 |
| Ozempic | Semaglutide | 92 | 15 |
| Sertraline Hcl | Sertraline Hcl | 91 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 26 |
| Clonazepam | Clonazepam | 87 | suppressed |
| Atenolol | Atenolol | 86 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | suppressed |
| Eliquis | Apixaban | 84 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 83 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | suppressed |
| Famotidine | Famotidine | 79 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 19 |
| Simvastatin | Simvastatin | 67 | 18 |
| Allopurinol | Allopurinol | 66 | 19 |
| Metformin Hcl | Metformin Hcl | 64 | 20 |
| Metformin Hcl Er | Metformin Hcl | 61 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 14 |
| Montelukast Sodium | Montelukast Sodium | 60 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 12 |
| Jardiance | Empagliflozin | 54 | 14 |
| Meloxicam | Meloxicam | 54 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Diazepam | Diazepam | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | 19 |
| Losartan Potassium | Losartan Potassium | 43 | 14 |
| Promethazine Hcl | Promethazine Hcl | 43 | 13 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | suppressed |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Carvedilol | Carvedilol | 34 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Vraylar | Cariprazine Hcl | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 11 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Cyclobenzaprine Hcl Er | Cyclobenzaprine Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $424.25 · 21 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR, YUPELRI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error